In November, I believed that shares of Globus Medical (NYSE:GMED) had seen a well deserved re-rating after a solid year ... but a deal for loss-making Nevro creates some discomfort among investors.

March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE ... decreased by 7.0% compared with the fourth quarter of 2023, and U.S. trial procedures decreased approximately 14.2% compared with the fourth ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Tuesday reported a loss of $53.1 million in its fourth quarter. On a per-share basis, the Redwood City ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

95.5% of Nevro shares are held by institutional investors ... that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient ...